Menu Search
Equities

Cryo-Cell International Inc

ZCY:FRA

Cryo-Cell International Inc

Actions
  • Price (EUR)7.40
  • Today's Change-0.55 / -6.92%
  • Shares traded1.00
  • 1 Year change+113.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 08:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

  • Revenue in USD (TTM)31.84m
  • Net income in USD-8.93m
  • Incorporated1989
  • Employees82.00
  • Location
    Cryo-Cell International Inc700 BROOKER CREEK BLVD, SUITE 1800OLDSMAR 34677United StatesUSA
  • Phone+1 (813) 749-2104
  • Fax+1 (813) 855-4745
  • Websitehttps://www.cryo-cell.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.